Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.

AMRX

$19.33

Updated: 24/09/2026, 08:07:09

Market Cap
$6.17B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Stock valuation chart
One-year closing share-price history for AMRX
Company Profile

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

USD
NASDAQ
CEO: Chirag K. Patel
Employees: 8,700
https://www.amneal.com
Asset Summaries
Latest generated summaries for AMRX

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for AMRX.
Share price
$19.33
Market cap
$6.17B
Exchange
NASDAQ
Currency
USD
CEO
Chirag K. Patel
Employees
8,700
IPO date
07/05/2018
Beta
1.242
Last dividend
$0.00
Day range
$18.74 – $20.17
52-week range
$9.49 – $21.18
1-day performance
-0.87%
1-year performance
103.69%
Current drawdown (1Y)
-8.71%
CIK
0001723128
CUSIP
03168L105
ISIN
US03168L1052
Created
07/12/2025, 02:04:28
Last update
24/09/2026, 08:07:09

Track Amneal Pharmaceuticals, Inc. with an AI analyst

See which prediction-market events move AMRX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to AMRX from your Railway `news_articles` table.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Zacks Investment Research • STOCK • 11/06/2026, 12:17:09

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

PRNewsWire • STOCK • 10/06/2026, 12:09:00

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

MarketBeat • STOCK • 09/06/2026, 17:05:58

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 15:32:09

Is Amneal a Buy Before Rytary Generic Erosion?

Zacks Investment Research • STOCK • 09/06/2026, 15:01:21

Amneal Stock Up on FDA Nod for Romidepsin Injection Solution

Zacks Investment Research • STOCK • 05/06/2026, 14:30:34

Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution

Proactive Investors • STOCK • 04/06/2026, 16:08:06

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

GlobeNewsWire • STOCK • 04/06/2026, 10:00:00

Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?

Zacks Investment Research • STOCK • 26/05/2026, 15:16:06

3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)

Zacks Investment Research • STOCK • 15/05/2026, 15:46:14

Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?

Zacks Investment Research • STOCK • 15/05/2026, 12:41:29

Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

Zacks Investment Research • STOCK • 08/05/2026, 14:16:06